REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 and Recent Corporate Highlights
- New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) accepted by the U.S. Food and Drug Administration (FDA) and granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024.
- The FDA Review Division determined that there does not appear to be a need for an advisory committee meeting at this time. However, the Division's review team will continue to consider the potential need for an advisory committee meeting during their ongoing review.
- Announced updates to its Board of Directors:
- Appointed Dawn Carter Bir, a seasoned biotechnology executive with over 30 years of industry executive leadership and strategic experience, to Soleno's Board of Directors.
- Current Board member Matthew Pauls, J.D., M.B.A assumed the role of Lead Independent Director.
- Soleno mourned the passing of former Chairman of the Board Ernest Mario, Ph.D. Dr. Mario served as Soleno's (formerly Capnia's) Chairman from 2007 through August 2024.
Financial Results
Soleno's current research and development efforts are primarily focused on advancing its lead product candidate, DCCR, for the treatment of PWS, through late-stage clinical development.
Third Quarter Ended September 30, 2024 Financial Results
Soleno used $14.9 million of cash in its operating activities during the three months ended September 30, 2024, and had $284.7 million of cash, cash equivalents and marketable securities.
Research and development expense was $30.1 million, which includes $18.5 million of non-cash stock-based compensation, for the three months ended September 30, 2024, compared to $6.0 million, which includes $0.9 million of non-cash stock-based compensation in the same period of 2023. Personnel and associated costs increased $2.4 million as we hired additional employees in support of our research and development activities. Consulting costs in support of our NDA submission and preparation for a submission to the European Medicines Agency increased $2.7 million, and we invested $1.3 million in supply chain activities in preparation for commercial launch. The cadence of our research and development expenditures will fluctuate depending upon the state of our clinical programs, the timing of manufacturing and other projects necessary to support the submission of our NDA and prepare for commercial launch. The $17.6 million of additional non-cash stock-based compensation being recognized in the period is predominantly due to performance-based RSU grants which partially vested upon the acceptance by the FDA of the NDA submission and fully vest upon the approval by the FDA (see table below).
General and administrative expense was $49.2 million, which includes $38.1 million of non-cash stock-based compensation, for the three months ended September 30, 2024, compared to $3.3 million, which includes $1.3 million of non-cash stock-based compensation, in the same period of 2023. Personnel and associated costs increased $3.0 million as we hired additional employees in preparation for commercial launch and in support of our increased business activities. Professional services expenses and other program costs associated with preparation for commercial launch, including medical affairs activities, increased by $5.9 million. The $36.8 million of additional non-cash stock-based compensation being recognized in the period is predominantly due to performance-based RSU grants which partially vested upon acceptance by the FDA of the NDA submission and fully vest upon approval by the FDA (see table below).
We are obligated to make cash payments of up to a maximum of $21.2 million to the former Essentialis stockholders upon the achievement of certain commercial milestones associated with the sales of DCCR in accordance with the terms of our merger agreement with Essentialis. The fair value of the liability for the contingent consideration payable by us achieving two commercial sales milestones of $100 million and $200 million in cumulative revenue in future years was estimated to be $14.5 million as of September 30, 2024, a $0.9 million increase from the estimate as of June 30, 2024.
Total other income, net, was $3.6 million for the three months ended September 30, 2024, compared to total other expense, net, of $0.5 million in the same period of 2023. The increase was primarily due to an increase in interest income driven by higher cash and cash equivalents, marketable securities and long-term marketable securities during the three months ended September 30, 2024, compared to the three months ended September 30, 2023.
Net loss was approximately $76.6 million, or $1.83 per basic and diluted share, for the three months ended September 30, 2024, and $10.9 million, or $0.95 per basic and diluted share, in the same period of 2023.
About PWS
The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, food pre-occupation, extreme drive to food seek and consume food that severely diminish the quality of life for patients with PWS and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant morbidities (e.g., obesity, diabetes, cardiovascular disease) and mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior). In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parent and caregivers) rated hyperphagia and 92.9% rated body composition as either the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder.
About DCCR (Diazoxide Choline) Extended-Release Tablets
DCCR is a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily. The parent molecule, diazoxide, has been used for decades in thousands of patients in a few rare diseases in neonates, infants, children and adults, but has not been approved for use in PWS. Soleno conceived of and established extensive patent protection for the therapeutic use of diazoxide, diazoxide choline and DCCR in patients with PWS. The DCCR development program is supported by data from five completed Phase 1 clinical studies in healthy volunteers and three completed Phase 2 clinical studies, one of which was in patients with PWS. In the PWS Phase 3 clinical development program, DCCR showed promise in addressing hyperphagia, the hallmark symptom of PWS, as well as several other symptoms such as aggressive/destructive behaviors, fat mass and other metabolic parameters. Diazoxide choline has received Orphan Drug Designation for the treatment of PWS in the U.S. and E.U., and Fast Track and Breakthrough Designations in the U.S.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the FDA's review of our NDA, market conditions, as well as risks and uncertainties inherent in Soleno's business, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
| Soleno Therapeutics, Inc.
Condensed Consolidated Balance Sheets (In thousands except share and per share data) | |||||||
| September 30, 2024 | December 31,
2023 | ||||||
| Assets | (unaudited) | ||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 48,413 | $ | 169,681 | |||
| Marketable securities | 208,363 | - | |||||
| Prepaid expenses and other current assets | 1,423 | 1,677 | |||||
| Total current assets | 258,199 | 171,358 | |||||
| Long-term assets | |||||||
| Property and equipment, net | 196 | 12 | |||||
| Operating lease right-of-use assets | 2,992 | 407 | |||||
| Intangible assets, net | 7,291 | 8,749 | |||||
| Long-term marketable securities | 27,945 | - | |||||
| Other long-term assets | 83 | 165 | |||||
| Total assets | $ | 296,706 | $ | 180,691 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 6,243 | $ | 3,149 | |||
| Accrued compensation | 3,408 | 3,135 | |||||
| Accrued clinical trial site costs | 1,762 | 3,393 | |||||
| Operating lease liabilities | 448 | 273 | |||||
| Other current liabilities | 3,101 | 1,555 | |||||
| Total current liabilities | 14,962 | 11,505 | |||||
| Long-term liabilities | |||||||
| Contingent liability for Essentialis purchase price | 14,464 | 11,549 | |||||
| Long-term lease liabilities | 2,581 | 130 | |||||
| Total liabilities | 32,007 | 23,184 | |||||
| Commitments and contingencies (Note 6) | |||||||
| Stockholders' equity | |||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding | - | - | |||||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 41,041,216 and 31,678,159 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 41 | 32 | |||||
| Additional paid-in-capital | 660,041 | 433,885 | |||||
| Accumulated other comprehensive gain | 895 | - | |||||
| Accumulated deficit | (396,278 | ) | (276,410 | ) | |||
| Total stockholders' equity | 264,699 | 157,507 | |||||
| Total liabilities and stockholders' equity | $ | 296,706 | $ | 180,691 | |||
| Soleno Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (In thousands except share and per share data) | |||||||||||||||
| Three Months Ended
September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Operating expenses | |||||||||||||||
| Research and development | $ | 30,138 | $ | 6,043 | $ | 57,082 | $ | 16,500 | |||||||
| General and administrative | 49,197 | 3,318 | 68,558 | 9,341 | |||||||||||
| Change in fair value of contingent consideration | 877 | 1,021 | 2,915 | 1,633 | |||||||||||
| Total operating expenses | 80,212 | 10,382 | 128,555 | 27,474 | |||||||||||
| Operating loss | (80,212 | ) | (10,382 | ) | (128,555 | ) | (27,474 | ) | |||||||
| Other income (expense), net | |||||||||||||||
| Change in fair value of warrants liabilities | - | (653 | ) | - | (652 | ) | |||||||||
| Interest income, net | 3,596 | 174 | 8,687 | 434 | |||||||||||
| Total other income (expense), net | 3,596 | (479 | ) | 8,687 | (218 | ) | |||||||||
| Net loss | $ | (76,616 | ) | $ | (10,861 | ) | $ | (119,868 | ) | $ | (27,692 | ) | |||
| Other comprehensive income (loss) | |||||||||||||||
| Net unrealized gain on marketable securities | 1,049 | - | 898 | - | |||||||||||
| Foreign currency translation adjustment | (1 | ) | (1 | ) | (3 | ) | (1 | ) | |||||||
| Total comprehensive loss | $ | (75,568 | ) | $ | (10,862 | ) | $ | (118,973 | ) | $ | (27,693 | ) | |||
| Net loss per common share, basic and diluted | $ | (1.83 | ) | $ | (0.95 | ) | $ | (3.08 | ) | $ | (2.65 | ) | |||
| Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share | 41,879,025 | 11,436,748 | 38,917,169 | 10,443,186 | |||||||||||
|
|